Clinical Trials Browser

Has results × Multiple Myeloma × Bortezomib × Clear all

NCT04181827 2026-04-13

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT01453101 2026-04-08

Flu-Mel-Vel

Phase 2 Completed

54 enrolled 8 charts

Multiple Myeloma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 11 charts 3 FDA

Multiple Myeloma

NCT01453088 2026-03-24

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Phase 2 Terminated

63 enrolled 11 charts

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Phase 1/2 Active not recruiting

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01919086 2026-03-02

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Phase 2 Completed

30 enrolled 13 charts

Multiple Myeloma

NCT00378105 2026-02-24

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

Phase 1/2 Active not recruiting

68 enrolled 9 charts

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 2 FDA

Multiple Myeloma

NCT05556616 2026-01-29

iinnovate-2

Phase 1 Terminated

15 enrolled 15 charts

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

Phase 3 Active not recruiting

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02441686 2026-01-13

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Phase 2 Completed

46 enrolled 13 charts

Multiple Myeloma

NCT01241708 2025-09-17

(Mel/MelVel)

Phase 3 Completed

148 enrolled 12 charts

Multiple Myeloma

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

706 enrolled 29 charts

Multiple Myeloma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1 Completed

15 enrolled 91 charts

Multiple Myeloma

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

36 enrolled 17 charts

Multiple Myeloma

NCT02224729 2025-04-30

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

24 enrolled 13 charts

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 5 FDA

Multiple Myeloma

NCT06868654 2025-04-23

DREAMM 7

Phase 3 Active not recruiting

72 enrolled 10 charts

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

Phase 3 Completed

1,085 enrolled 22 charts 2 FDA

Multiple Myeloma

NCT03544281 2025-03-18

DREAMM 6

Phase 1/2 Completed

153 enrolled 91 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

Phase 3 Active not recruiting

302 enrolled 10 charts

Multiple Myeloma

NCT01539083 2025-02-04

VCAT

Phase 3 Completed

256 enrolled 13 charts

Multiple Myeloma

NCT02874742 2025-02-04

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

224 enrolled 19 charts

Multiple Myeloma

NCT04246047 2024-10-24

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 3 FDA

Multiple Myeloma

NCT02375555 2024-10-01

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

Phase 2 Completed

40 enrolled 18 charts

Multiple Myeloma

NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Phase 1/2 Completed

20 enrolled 9 charts

GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 3 FDA

Multiple Myeloma, Recurrence

NCT02654990 2024-07-12

PANORAMA_3

Phase 2 Completed

248 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Completed

95 enrolled 13 charts

LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

NCT00734149 2023-11-07

MVP

Phase 2 Completed

45 enrolled 8 charts

Multiple Myeloma

NCT01177683 2023-10-06

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Phase 1/2 Terminated

32 enrolled 18 charts

Multiple Myeloma

NCT02755597 2023-08-22

Bellini

Phase 3 Completed

291 enrolled 24 charts

Multiple Myeloma

NCT01734928 2023-06-06

OPTIMISMM

Phase 3 Completed

559 enrolled 16 charts

Multiple Myeloma

NCT02440464 2023-01-04

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

Phase 2 Completed

57 enrolled 22 charts

Hematologic Diseases, Multiple Myeloma

NCT03481556 2022-12-19

ANCHOR

Phase 1/2 Terminated

56 enrolled 22 charts

Multiple Myeloma

NCT01568866 2022-11-14

ENDEAVOR

Phase 3 Completed

929 enrolled 21 charts

Multiple Myeloma

NCT00784823 2022-08-11

Mel-Vel

Phase 1/2 Completed

32 enrolled 8 charts

Multiple Myeloma

NCT00464178 2022-07-20

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

7 enrolled 5 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01849783 2022-05-11

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Phase 2 Completed

41 enrolled 12 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01109004 2021-12-09

BMT CTN 0702

Phase 3 Completed

758 enrolled 21 charts

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Phase 3 Terminated

269 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT02951819 2021-10-08

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Phase 2 Completed

101 enrolled 17 charts

Multiple Myeloma

NCT02481934 2021-08-20

NK-VS-MM

Phase 1 Completed

5 enrolled 6 charts

Multiple Myeloma

NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Phase 2 Completed

45 enrolled 8 charts

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

NCT02703779 2021-06-18

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

Phase 2 Completed

101 enrolled 11 charts

Multiple Myeloma